The American biopharmaceutical company AbbVie Inc. intends to raise $8 billion through the placement of investment-grade bonds to finance the acquisition of Apogee Therapeutics Inc. This is reported by foreign media.
AbbVie plans to sell the bonds in nine tranches with maturities ranging from two to 40 years. AbbVie last entered the market in February, selling $8 billion in bonds to repay debt and finance corporate expenses.
In June, AbbVie entered into an agreement to acquire Apogee for $10.9 billion ($90.4 per share, 49% higher than the closing price on June 19, 2026) in order to expand its portfolio of anti-inflammatory drugs amid growing competition.
The Apogee line includes the drug zumilokibart (zumilokibart) for the treatment of atopic dermatitis or eczema. The drug has great potential for sales growth and may become an addition to AbbVie's line of immunological drugs.
In May 2026, Blackstone Inc. provided Apogee with $1.3 billion in financing to market zumilokibart in exchange for royalties from future sales. In addition, zumilokibart is considered as a potential competitor to the French drug Sanofi Dupixent and sets a new bar in the treatment of atopic dermatitis.
The deal between AbbVie and Apogee will be one of the latest in a series of major deals in the pharmaceutical sector. In 2019, AbbVie bought out botox manufacturer Allergan Inc. for $63 billion, and in 2026, British pharmaceutical company GSK Plc signed an agreement to acquire Nuvalent Inc. for $10.6 billion..
AbbVie Inc. is an American multinational biopharmaceutical company headquartered in Chicago, Illinois. The company develops drugs for the treatment of autoimmune diseases, including rheumatoid arthritis, Crohn's disease, etc.
Apogee Therapeutics is a biotech company developing biologics for the treatment of chronic atopic dermatitis. The headquarters is located in Waltham, Massachusetts.
Read our Telegram channel "Mergers and Acquisitions. AK&M».
Our channel at MAX is "Mergers and Acquisitions. AK&M».

